Therapeutic compounds as inhibitors of the orexin-1 receptor

1. A method of alleviating a disease or condition selected from anxiety disorders; panic disorders; mood disorders; addiction including substance dependence, alcohol dependence, nicotine dependence or gambling disorder; and eating disorders, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:

wherein:

R a is ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, or cyclopropylmethyl, each of which is optionally substituted by one or more fluoro;

R b is:

(i) hydrogen;

(ii) a (1-4C)alkyl which is optionally substituted by one or more fluoro;

(iii) a (3-6C)cycloalkyl which is optionally substituted by one or more fluoro; or

(iv) a (3-6C)cycloalkyl(1-2C)alkyl which is optionally substituted by one or more fluoro;

X is a group:

—X 0 —(CH 2 ) n —

wherein

X 0 is —O—, —N(R 1 )—, —C(O)—N(R 1 )—, —N(R 1 )C(O)N(R 1 )— or —S—;

n is 0 or 1;

R 1 is hydrogen or a (1-2C)alkyl group which is optionally substituted by one or more substituents selected from fluoro, hydroxyl, NR 1a R 1b , (1-2C)alkoxy and (1-2C)haloalkoxy;

R 1a and R 1b are each independently hydrogen or (1-2C)alkyl; or R 1a and R 1b are linked such that, together with the nitrogen atom to which they are attached, they form a 4, 5 or 6 membered heterocyclic ring;

Ar is aryl or heteroaryl, each of which is optionally substituted with one or more substituents selected from halo, cyano, nitro and a group of the formula:

-L 1 -X 1 —R 6

wherein

L 1 is absent or a linker group of the formula —[CR 7 R 8 ] r — in which r is an integer selected from 1, 2, 3 and 4, and R 7 and R 8 are each independently selected from hydrogen, halo, hydroxy and a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 7 and R 8 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 1 is absent or selected from —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 9 )—, —N(R 9 )—C(O)—, —C(O)—N(R 9 )—, —N(R 9 )—C(O)O—, —OC(O)—N(R 9 )—, —N(R 9 )C(O)N(R 10 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 9 )—, —N(R 9 )SO 2 — and —S(O)(═NR 10 )—, wherein R 9 and R 10 are hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl; and

R 6 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-2C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, or heteroaryl-(1-2C)alkyl,

and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 2 -X 2 —R 11

wherein

L 2 is absent or a linker group of the formula —[CR 12 R 13 ] s — in which s is an integer selected from 1, 2, 3 and 4, and R 12 and R 13 are each independently hydrogen or a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 12 and R 13 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 2 is absent or selected from —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 14 )—, —N(R 14 )—C(O)—, —C(O)—N(R 14 )—, —N(R 14 )—C(O)O—, —OC(O)—N(R 14 )—, —N(R 14 )C(O)N(R 15 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 14 )—, —N(R 14 )SO 2 — and —S(O)(═NR 14 )—, wherein R 14 and R 15 are hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl; and

R 11 is hydrogen or a (1-6C)alkyl (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents;

Q is aryl or heteroaryl, each of which is optionally substituted with one or more R z substituents, wherein R z is halo, cyano, nitro, or a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent or a linker group of the formula —[CR 31 R 32 ] t — in which t is an integer selected from 1, 2, 3 and 4, and R 31 and R 32 are each independently hydrogen or a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 31 and R 32 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 3 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —N(R 33 )—C(O)O—, —OC(O)—N(R 33 )—, —N(R 33 )C(O)N(R 34 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 33 )—, —N(R 33 )SO 2 — or —S(O)(═NR 33 )—, wherein R 33 and R 34 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl and (3-6C)cycloalkyl; and

R 30 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-2C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, or heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer selected from 1, 2, 3 and 4, and R 36 and R 37 are each independently hydrogen or a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 36 and R 37 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 4 is absent or selected from —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 38 )—, —N(R 38 )—C(O)—, —C(O)—N(R 38 )—, —N(R 38 )—C(O)O—, —OC(O)—N(R 38 )—, —N(R 38 )C(O)N(R 39 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 38 )—, —N(R 38 )SO 2 — and —S(O)(═NR 38 )—, wherein R 38 and R 39 are hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl; and

R 35 is hydrogen or a (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents;

or a pharmaceutically acceptable salt or solvate thereof.

2. The method according to claim 1 , wherein R a is ethyl or cyclopropyl, each of which is optionally substituted by one or more fluoro.

3. The method according to claim 1 , wherein R a is ethyl optionally substituted by one or more fluoro.

4. The method according to claim 1 , wherein R a is ethyl.

5. The method according to claim 1 , wherein R b is:

hydrogen; or

a (1-4C)alkyl which is optionally substituted by one or more fluoro.

6. The method according to claim 1 , wherein R b is hydrogen or methyl.

7. The method according to claim 1 , wherein R b is methyl.

8. The method according to claim 1 , wherein Ar is aryl or heteroaryl, each of which is optionally substituted with one or more substituents selected from halo, cyano, nitro and a group of the formula:

-L 1 -X 1 —R 6

wherein

L 1 is absent or a linker group of the formula —[CR 7 R 8 ] r — in which r is an integer 1 or 2, and R 7 and R 8 are each independently hydrogen, halo, or a (1-2C)alkyl group which is optionally substituted by one or more fluoro substituents;

X 1 is absent or selected from —O—, —N(R 9 )—, —S—, —SO—, and —SO 2 —, wherein R 9 is hydrogen or (1-2C)alkyl; and

R 6 is hydrogen, (1-4C)alkyl, phenyl, phenyl(1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 2 -X 2 —R 11

wherein

L 2 is absent or a linker group of the formula —[CR 12 R 13 ] s — in which s is an integer 1 or 2, and R 12 and R 13 are each independently hydrogen or a (1-2C)alkyl group;

X 2 is absent or selected from —O—, —N(R 14 )—, —S—, —SO—, and —SO 2 —, wherein R 14 is hydrogen or (1-2C)alkyl; and

R 11 is hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents.

9. The method according to claim 1 , wherein Ar is phenyl, naphthyl or a mono or bicyclic heteroaryl, each of which is optionally substituted with one or more substituents selected from halo, cyano, nitro and a group of the formula:

-L 1 -X 1 —R 6

wherein

L 1 is absent or a linker group of the formula —[CR 7 R 8 ] r — in which r is an integer 1 or 2, and R 7 and R 8 are each independently hydrogen, halo, or a (1-2C)alkyl group which is optionally substituted by one or more fluoro substituents;

X 1 is absent or selected from —O—, —N(R 9 )—, —S—, —SO—, and —SO 2 —, wherein R 9 is hydrogen or (1-2C)alkyl; and

R 6 is hydrogen, (1-4C)alkyl, phenyl, phenyl(1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 2 -X 2 —R 11

wherein

L 2 is absent or a linker group of the formula —[CR 12 R 13 ] s — in which s is an integer 1 or 2, and R 12 and R 13 are each independently hydrogen or a (1-2C)alkyl group;

X 2 is absent or selected from —O—, —N(R 14 )—, —S—, —SO—, and —SO 2 —, wherein R 14 hydrogen or (1-2C)alkyl; and

R 11 is hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents.

10. The method according to claim 1 , wherein Q is aryl or heteroaryl, each of which is optionally substituted with one or more R z substituents, wherein R z is halo, cyano, nitro, or a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent or a linker group of the formula —[CR 31 R 32 ] t — in which t is an integer selected from 1 or 2, and R 31 and R 32 are each independently hydrogen or a (1-4C)alkyl group;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, and —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen, (1-4C)alkyl, phenyl, phenyl(1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer 1 or 2, and R 36 and R 37 are each independently hydrogen or a (1-2C)alkyl group;

X 4 is absent or selected from —O—, —N(R 38 )—, —S—, —SO—, and —SO 2 —, wherein R 38 is hydrogen or (1-2C)alkyl; and

R 35 is hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents.

11. The method according to claim 1 , wherein Q is a group having the following structure:

wherein ring Q is selected from phenyl, 5-6 membered monocyclic heteroaryl, and 9-10 membered bicyclic heteroaryl; a is an integer 0-1; and b is an integer 0-5; and

R z1 is a substituent group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent or selected from —O—, —N(R 33 )—, —S—, —SO— and —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen, (1-4C)alkyl, phenyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer selected from 1, 2 and 3, and R 36 and R 37 are each independently hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 36 and R 37 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 4 is absent or selected from —O—, —C(O)—, —N(R 38 )—, —N(R 38 )—C(O)—, —C(O)—N(R 38 )—, —N(R 38 )C(O)N(R 39 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 38 )—, —N(R 38 )SO 2 — and —S(O)(═NR 38 )—, wherein R 38 and R 39 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl and (3-6C)cycloalkyl; and

R 35 is hydrogen or a (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents,

R z2 is selected from halo, cyano, nitro, and a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, and —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen, (1-4C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer selected from 1, 2 and 3, and R 36 and R 37 are each independently hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 36 and R 37 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 4 is absent or selected from —O—, —C(O)—, —N(R 38 )—, —N(R 38 )—C(O)—, —C(O)—N(R 38 )—, —N(R 38 )C(O)N(R 39 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 38 )—, —N(R 38 )SO 2 — and —S(O)(═NR 38 )—, wherein R 38 and R 39 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl and (3-6C)cycloalkyl; and

R 35 is hydrogen or a (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents.

12. The method according to claim 11 , wherein ring Q is a group having any one of the following structures, W1-W7:

wherein X 1 , X 2 and X 3 are each a heteroatom selected from O, N and S; a is an integer 0-1; and b is an integer 0-5.

13. The method according to claim 11 , wherein a is 1 and b is 0 or 1.

14. The method according to claim 11 , wherein R z1 is a substituent group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent; and

R 30 is phenyl or a C- or N-linked 5-6 membered heteroaryl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from halo, cyano and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent;

X 4 is absent; and

R 35 is hydrogen or a (1-2C)alkyl group which is optionally substituted by one or more fluoro substituents.

15. The method according to claim 11 , wherein R z2 is selected from halo, cyano, and a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, and —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen or (1-4C)alkyl,

and wherein R 30 is optionally further substituted by one or more fluoro atoms.

16. The method according to claim 1 , wherein said compound has the structural formula IA shown below

wherein

R b is selected from:

(i) (1-4C)alkyl which is optionally substituted by one or more fluoro;

(ii) (3-6C)cycloalkyl which is optionally substituted by one or more fluoro; or

(iii) (3-6C)cycloalkyl(1-2C)alkyl which is optionally substituted by one or more fluoro;

R z2 is selected from halo, cyano, nitro, and a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, and —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen, (1-4C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, and a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer selected from 1, 2 and 3, and R 36 and R 37 are each independently hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 36 and R 37 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 4 is absent or selected from —O—, —C(O)—, —N(R 38 )—, —N(R 38 )—C(O)—, —C(O)—N(R 38 )—, —N(R 38 )C(O)N(R 39 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 38 )—, —N(R 38 )SO 2 — and —S(O)(═NR 38 )—, wherein R 38 and R 39 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl and (3-6C)cycloalkyl; and

R 35 is hydrogen or a (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents.

17. The method according to claim 16 , wherein

R b is (1-4C)alkyl optionally substituted by fluoro;

R z2 is selected from halo, cyano, nitro, and a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, or —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen or (1-4C)alkyl;

and wherein R 30 is optionally further substituted by one or more fluoro atoms.

18. The method according to claim 16 , wherein

R b is methyl optionally substituted by fluoro;

R z2 is halo, methyl, methoxy, CF 3 or OCF 3 ;

Ar is pyridyl, pyrimidinyl, pyrazinyl, which is optionally substituted by one or more substituent groups selected from halo, cyano, hydroxyl, mercapto, amino, carbamoyl, sulphamoyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy, (1-2C)haloalkoxy, (1-2C)alkylamino, di-[(1-2C)alkyl]amino, (1-2C)alkylthio, (1-2C)alkylsulphinyl, (1-2C)alkylsulphonyl, (1-2C)alkoxycarbonyl, N-(1-2C)alkylcarbamoyl, N,N-di-[(1-2C)alkyl]carbamoyl, (2C)alkanoyl, (2C)alkanoyloxy, (2C)alkanoylamino, N-(1-2C)alkylsulphamoyl and N,N-di-[(1-2C)alkyl]sulphamoyl.

19. The method of claim 1 , wherein the compound is selected from:

(S)—N-(1-(5-chloropyridin-2-yl)amino)butan-2-yl)-N,5-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)butan-2-yl)-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-2-methyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-2-methyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-N,2-dimethyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-(5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3,3-dimethylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(2-((5-chloropyridin-2-yl)amino)-1-cyclopropylethyl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)propan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-cyclopropyl-[1,1′-biphenyl]-2-carboxamide;

(S)-5-chloro-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-fluoro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)-5-bromo-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethoxy)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,5-dimethyl-2-morpholinobenzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-(dimethylamino)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)nicotinamide;

(S)-5-chloro-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethyl-5-phenylthiazole-4-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-phenyl-1H-indole-3-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((4-fluorobenzyl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(quinazolin-2-yloxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((4-phenylpyrimidin-2-yl)oxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((1-methyl-1H-benzo[d]imidazol-2-yl)oxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((4-phenylpyrimidin-2-yl)amino)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(quinazolin-2-ylamino)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4,6-dimethylpyrimidin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((1-methyl-1H-benzo[d]imidazol-2-yl)amino)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridazin-3-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)benzamide;

(S)—N-(1-(benzo[d]oxazol-2-ylamino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-(benzo[d]thiazol-2-ylamino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)-5-chloro-N-(1-((5-chloro-3-nitropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,5-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,1-dimethyl-1H-indole-3-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethylquinoline-4-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-(trifluoromethoxy)benzamide;

(S)-5-chloro-N-methyl-N-(1-((6-methylpyridin-2-yl)amino)butan-2-yl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridin-3-yl)amino)butan-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridin-3-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-(4-fluorobenzamido)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4-fluorobenzyl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(3-phenylureido)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4-chlorophenyl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((3-amino-5-chloropyridin-2-yl)amino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-N-(1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-(benzo[d]oxazol-2-ylamino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-(benzo[d]thiazol-2-ylamino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((5-chlorobenzo[d]oxazol-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(1-(quinoxalin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-N-(1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-cyclopropyl-2-((5-(trifluoromethyl)pyrimidin-2-yl)amino)ethyl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(1-(quinolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((1,5-naphthyridin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)-5-chloro-N-methyl-N-(1-(quinolin-2-ylamino)butan-2-yl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,3-dimethyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)quinoline-8-carboxamide;

(S)-6-chloro-N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)quinoline-8-carboxamide;

(S)-3-(dimethylamino)-N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N,6-dimethyl-N-(1-(methyl(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((2-methoxyethyl)(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(pyrimidin-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)—N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,4,5-trimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-methoxy-N,4-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(4,4,4-trifluoro-1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(1H-1,2,4-triazol-1-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)—N,6-dimethyl-3-(1H-pyrazol-1-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)-2-fluoro-N-methyl-6-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)benzamide; and

(S)-6-methoxy-N-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

or a pharmaceutically acceptable salt or solvate thereof.

20. The method of claim 1 , wherein the substance dependence is cocaine, opiates, cannabis or prescription drug dependence.

21. The method of claim 1 , wherein the anxiety disorder is selected from generalized anxiety disorder, post-traumatic stress disorder, acute stress disorder, social anxiety disorder, agoraphobia, obsessive compulsive disorder, trichotillomania and body dysmorphic disorder.

22. The method of claim 1 , wherein the mood disorder is selected from depressive disorders, bipolar disorders, bipolar mania and bipolar depression.

23. The method of claim 1 , wherein the eating disorder is selected from binge eating, bulimia nervosa and anorexia nervosa.